[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100252049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":52,"collaborators":54,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":10,"maxAge":64,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Associazione Italiana Ematologia Oncologia Pediatrica","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients NB with SCI",null,"Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse\u002Fprogression).",[13],"Other: survival and late effects",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"survival and late effects",[9],[19],{"name":20,"affiliation":21,"role":22},"Riccardo Haupt, MD","Istituto Giannina Gaslini Genova","PRINCIPAL_INVESTIGATOR",[24,29],{"name":20,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","01056363462","+39","riccardohaupt@ospedale-gaslini.ge.it",{"name":30,"role":25,"phone":31,"phoneExt":27,"email":32},"tiziana landi","051\u002F2144667","segreteria@aieop.org",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Istituto Giannina Gaslini","RECRUITING","Genova","16147","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],11.87211,45.21604,{"lat":45,"lon":44},[48,49],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":28},{"name":50,"role":25,"phone":10,"phoneExt":10,"email":51},"Stefania Sorrentino","stefaniasorrentino@ospedale-gaslini.ge.it",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55],{"name":35,"class":6},"100252049","prospective-study-registry-of-peripheral-neuroblastic-tumours-presenting-with-spinal-canal-involvement-sci-100252049",false,"NCT02559804","Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)","NB-SCI","Inclusion Criteria:\n\n* Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse\u002Fprogression)\n* No previous chemotherapy, except steroids, in the last 6 months\n* Age \\\u003C18 years\n* Minimal planned follow-up of 5 years\n* Parent\u002Fpatient written informed consent (Appendix 1(A,B,C))\n\nExclusion Criteria:\n\n* Invasion of intervertebral foramina only","ALL","18 Years",{"count":66,"type":67},150,"ESTIMATED","5 Years","OBSERVATIONAL","To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes",[72],"Neuroblastic Tumors","2024-04-12",{"date":75,"type":76},"2024-04-15","ACTUAL",{"date":78,"type":10},"2014-05",{"date":80,"type":67},"2029-05",{"name":5,"class":6},1]